4 completed. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Phase 1 | 1 | Completed 1 |
Follow DNK 333: new trials by email Literature Review of DNK 333 trials Research Report on DNK 333
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of DNK333 in Atopic Dermatitis Patients DNK333 5 mg, Placebo to 5 mg, DNK333 25 mg - Pruritus in Patients With Atopic Dermatitis | Phase 2 | Completed | Novartis Pharmaceuticals | 80 | 2009-11-01 | 2017-03-21 |
| Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) DNK333, Placebo - Irritable Bowel Syndrome With Diarrhea (IBS-D) | Phase 2 | Completed | Novartis | 180 | 2006-09-01 | 2017-02-27 |
| Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) in Women With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) DNK333 - Irritable Bowel Syndrome | Phase 2 | Completed | Novartis | 135 | 2004-04-01 | 2008-06-17 |
| Efficacy of DNK333 in Patients With COPD and Cough DNK333 100 mg twice daily, Placebo - Chronic Obstructive Pulmonary Disease | Phase 1 / Phase 2 | Completed | Novartis | 28 | 2003-09-01 | 2011-02-01 |
Diarrhea (2) · Gastrointestinal Diseases (2) · Cough (1) · Dermatitis (1) · Eczema (1) · Irritable Bowel Syndrome (1) · Pruritus (1) · Pulmonary Disease, Chronic Obstructive (1)
Novartis (3) · Novartis Pharmaceuticals (1)
United States (2) · Canada (1) · Germany (1) · Netherlands (1) · United Kingdom (1)